The disappointing August jobs report may be troublesome for the economy, but it is positive for high yield investors.
The rich did indeed get richer over the past 3 years according to a new Federal Reserve report.
Sanofi and Regeneron revealed this week their experimental cholesterol-lowering drug nearly halved the number of heart attacks and strokes in a clinical trial.
Zumiez posted second quarter earnings of $0.26 a share on revenue of $177 million.
The bull run in U.S. stocks is creating a great deal of complacency, said James Macey, portfolio manager at Allianz Global Investors.
Google shares will move another leg higher once it finally monetizes assets other than search like Android, Chrome and its GMail.
Only in the unlikely event of a Eurozone breakup will Europe's current troubles infect the U.S. economy, said Joseph Davis, Global Chief Economist at Vanguard.
Pernod-Ricard's China business is stabilizing after a slowdown in cognac sales forced the global spirits-seller to revise guidance earlier this year, said the company's Deputy CEO and COO Alexandre Ricard.
PVH posted second quarter earnings of $1.51 a share on revenue of $1.98 billion.
Zeltiq's non-invasive fat removal system has the potential to replicate the success seen by Botox, said Michael Balkin, portfolio manager for the William Blair Small Cap Growth Fund.